REYKJAVIK, ICELAND – 9 May 2022 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), the clinical-stage biopharmaceutical company developing disease-modifying therapeutics for chronic respiratory disorders, has appointed two new non-executive board members following the departure of Robert Helgason, who stepped down at the Company’s AGM on 26 April 2022.
Dr Isaac Cohen is currently Founder, President and CEO of Iaterion, Inc. and brings over 20 years’ experience in all phases of drug development and biopharmaceutical company management, from start-up to NASDAQ listing. He was previously Founder, Chairman and CEO of Bionovo, Inc. having also been a guest scientist at the University of California, San Francisco (UCSF) Center for Reproductive Sciences and the Comprehensive Cancer Center, and spending 20 years in private clinical practice in Berkeley, CA.
Dr. Eugen Steiner is a Venture Partner at venture capital fund HealthCap and has 35 years’ executive management experience of multistage life science companies, having raised over 100 million EUR from European and US investors. He is currently CEO of Nordic Vision Clinics AB and sits on the Boards of several public and private life science companies as well as the Stockholm School of Entrepreneurship. A former practicing physician, Dr. Steiner received his medical degree and PhD from the Karolinska Institute.
Robert Helgason is stepping down from the Board of EpiEndo to focus on his role as Founder and CEO of KOT ehf.
EpiEndo’s Board of Directors also includes Prof. Clive Page, Ívar Guðjónsson, Dr. Carl-Johan Spak, Magnús Berg Magnússon, Dr. Hilmar Bragi Janusson, and José Fernando Figueiredo as an observer.
Prof. Clive Page, Chairman of EpiEndo, said:
“We’d like to thank Robert for his valuable input at EpiEndo and are pleased to welcome Isaac and Eugen to the Board. They bring broad international and industry experience from drug development to scaling up businesses, which will be invaluable as we grow.”
Maria Bech, CEO of EpiEndo added:
“I look forward to working with this new Board of Directors, which brings a wealth of expertise in key sector and commercial areas, to progress EpiEndo into its next phase of development”.
Dr Isaac Cohen (left) and Dr Eugen Steiner (right). High resolution images available on request.
About EpiEndo Pharmaceuticals (www.epiendo.com)
EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to inflammatory disorders that focuses on enhancement of epithelial barrier integrity as a critical pathophysiological factor underlying the etiology of a number of major diseases. Epithelial cells are a key component of the barrier that makes up human lung tissue and other organs such as the gut and skin. Compromised integrity of this barrier is implicated in the progression and non-resolution of several chronic inflammatory diseases.
EpiEndo is developing a proprietary portfolio of non-antibiotic macrolide drugs called Barriolides, with promise as first-in-class disease-modifying therapeutics, to address the huge global burden of chronic diseases of the lung and other organs where there is significant unmet medical need. EpiEndo’s lead drug candidate, EP395, aims to be the first on-market oral, non-antibiotic, barrier strengthening and anti-inflammatory macrolide for the treatment of COPD.
For more information please contact email@example.com.